{"filings":[{"id":814925,"accession_number":"0001437749-26-019199","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2026-06-02T21:41:56+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Nuo Therapeutics secures $2M loan facility; issues warrants at $1.50 strike","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended loan agreement increases aggregate commitment by $400k to $2.0M; $675k funded on May 29, 2026.","Interest rate raised to 12% on all outstanding notes; interest payable via warrants, not cash.","Warrants issued at $1.50 exercise price, expiring Jan 23, 2031; includes diverse warrant types.","Lenders include director Scott Pittman (>10% owner) and Paul Jacobs (>5% owner); proceeds for working capital.","Mandatory prepayment triggers upon equity financing ≥$5M, change of control, or default."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":444876,"accession_number":"0001437749-26-017116","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2026-05-14T21:11:29+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuo Therapeutics Q1 revenues up 169% YoY to $1.3M; operating loss narrows","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $1.3M, including $1.22M product sales, up 169% YoY and 20% sequential.","Aurix branded product revenue rose over 30% sequentially versus Q4 2025.","Net operating loss improved to $446,000 from $745,000 in Q1 2025.","Entered $1.0M Loan and Security Agreement to fund growth as company approaches breakeven.","CEO cites strong Aurix demand and favorable Medicare reimbursement shift for autologous PRP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1302115.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101194,"accession_number":"0001437749-26-002078","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Nuo Therapeutics secures up to $1.6M loan with 10%-12% PIK interest paid in warrants; insider participation","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan agreement for $1.0M initial + $600K second tranche (Sept 30, 2026); $1.0M funded Jan 23, 2026.","Interest 10% annual on initial note, rising to 12% if second tranche is taken; accrued interest paid only in warrants at maturity.","Principal repaid in 8 equal quarterly installments from Mar 31, 2027 to Dec 31, 2028; early prepayment fee 1.5-2.75% of principal paid in warrants.","Lenders include director/10% owner Scott Pittman ($200K) and >5% owner Paul Jacobs ($300K); each received initial and potential second warrants.","Warrants exercisable at $1.50/share, expiring Jan 23, 2031; up to 226,000 interest warrant shares issuable at maximum borrowing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117540,"accession_number":"0001437749-25-038091","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nuo Therapeutics shareholders elect four directors and ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All four director nominees elected: David E. Jorden, Paul D. Mintz, Scott M. Pittman, C. Eric Winzer.","Ratification of MaloneBailey LLP as auditor approved with 35,917,807 for, 12,899 against.","Advisory vote on named executive officer compensation passed with 33,653,458 for, 40,106 against.","Broker non-votes of 2,237,142 noted for director election and say-on-pay items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117539,"accession_number":"0001437749-25-030813","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["5.02","5.08","8.01"],"status":"ready","headline":"Nuo Therapeutics raises CEO and COO salaries, sets Dec 16 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO David E. Jorden salary increased to $325,000 effective Oct 1, 2025.","COO Peter A. Clausen salary increased to $290,000 effective same date.","Annual meeting scheduled for Dec 16, 2025 at Houston principal executive office.","Shareholder proposals and director nominations deadline is Oct 20, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150713,"accession_number":"0001437749-25-017214","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Nuo Therapeutics enters interim sales agency agreement with Smith+Nephew for Aurix products","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to Distribution Agreement grants Smith+Nephew interim sales agent role for Nuo Aurix brand to certain Smith+Nephew customers.","Smith+Nephew receives commission on net sales of Nuo branded products sold to its customers under interim arrangement.","Interim agency terminates by Dec 31, 2025 or earlier with 30 days written notice.","Underlying five-year Distribution Agreement for Nuo to supply private-label Aurix to Smith+Nephew remains in effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203270,"accession_number":"0001437749-24-029602","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Nuo Therapeutics raises $849k in private placement of 1.13M shares at $0.75/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $849,125 from sale of 1,132,167 shares at $0.75 per share.","Principal stockholder Charles E. Sheedy invested $93,750 in the placement.","Proceeds to be used for working capital; shares outstanding increase to 46,598,405.","Shares sold under Section 4(a)(2) and Rule 506 without registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219613,"accession_number":"0001437749-24-021407","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Pacific Medical exercises full warrant for 356,889 shares of Nuo Therapeutics common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pacific Medical exercised warrant for 270,000 shares at $0.56/share, raising $151,200 in cash proceeds.","Remaining 230,000 shares exercised on cashless basis, resulting in issuance of 86,889 shares.","Total shares issued: 356,889; outstanding shares now 45,466,238."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219612,"accession_number":"0001437749-24-019961","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Nuo Therapeutics dismisses auditor Marcum, engages MaloneBailey; cites material weaknesses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective June 7, 2024, dismissed Marcum LLP as independent auditor; engaged MaloneBailey, LLP for FY 2024.","Marcum's reports for FY2023 and FY2022 included going-concern explanatory paragraphs.","Identified material weaknesses: insufficient accounting staff and lack of effective internal control over financial reporting.","No disagreements with Marcum on accounting principles or audit scope prior to dismissal.","Marcum's letter to SEC agreeing with disclosures filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219611,"accession_number":"0001437749-24-017754","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Nuo Therapeutics raises $650,875 in private placement of 867,833 shares at $0.75/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $650,875 from sale of 867,833 shares of common stock at $0.75 per share.","Insiders invested $187,500 total: Scott Pittman ($101,250), Peter Clausen ($11,250), Charles Sheedy ($75,000).","Proceeds to be used for working capital; shares sold under Rule 506(b) of the Securities Act.","Post-closing shares outstanding increased to 45,109,349."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219610,"accession_number":"0001437749-24-012214","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Nuo Therapeutics delays annual 10-K filing to April 19 for audit finalization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company will not file Form 10-K by April 16 as previously expected.","Delay due to independent auditor completing review of 2023 audited financial statements.","Filing now expected by April 19, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256948,"accession_number":"0001437749-23-034949","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Nuo Therapeutics raises $962,500 in private placement of 1.925M shares at $0.50/share","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Sold 1,925,000 common shares at $0.50 each for gross proceeds of $962,500.","Proceeds will be used for working capital purposes.","Participants include director Scott Pittman ($300k), COO Clausen ($10k), and stockholder Sheedy ($75k).","Total shares outstanding after placement: 44,241,516.","Offering was exempt under Section 4(a)(2) of the Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274273,"accession_number":"0001437749-23-021942","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Nuo Therapeutics raises $1.035M in private placement at $2.00/share; insiders participate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $1,035,000 from sale of 517,500 shares of common stock at $2.00 per share.","Participants include director Scott Pittman ($200k), COO Peter Clausen ($50k), stockholder Charles Sheedy ($125k).","Proceeds will be used for working capital purposes.","Post-offering outstanding shares are 42,316,516.","Shares sold in unregistered transaction under Section 4(a)(2) and Rule 506."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330856,"accession_number":"0001437749-22-028414","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2022-12-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nuo Therapeutics shareholders approve all proposals at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Re-elected David E. Jorden, C. Eric Winzer, Scott M. Pittman, and Paul D. Mintz as directors.","Ratified Marcum LLP as independent auditor for FY2022 with 27,697,944 votes for, 1,074 against.","Advisory vote on executive compensation approved with 26,692,397 for, 5,370 against, 5,000 abstain.","Advisory vote on frequency set to every three years based on 23,767,794 votes for three years.","Approved amendment to 2016 Omnibus Incentive Compensation Plan with 26,188,825 for, 7,988 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348375,"accession_number":"0001437749-22-023298","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2022-09-30T23:59:59+00:00","items":["5.08","8.01"],"status":"ready","headline":"Nuo Therapeutics sets 2022 Annual Meeting for Dec 2; record date Sept 30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual Meeting will be held at 8285 El Rio, Suite 190, Houston, Texas on December 2, 2022.","Stockholders of record as of September 30, 2022 are entitled to vote.","Deadline for shareholder proposals and director nominations is October 10, 2022.","Proposals must be submitted in writing to Secretary David Jorden at the company's address."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348374,"accession_number":"0001437749-22-021470","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2022-08-30T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Nuo Therapeutics secures $500K equity investment from distributor Pacific Medical; raises $4.5M YTD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PacMed invests $500K for 500K shares at $1.00; receives two warrants for up to 450K shares tied to sales quotas.","PacMed can earn up to 300K milestone shares if cumulative sales reach $4.5M–$12.5M over 2024–2025 periods.","Company raised ~$4.5M in working capital equity in 2022, including this deal, to support Aurix commercial re-launch.","Distribution network covers ~30% of U.S. population via 10 entities; PacMed contributes over 40 sales representatives.","Stock approved for OTCQB trading; uplisting to national securities exchange considered as a future option."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365072,"accession_number":"0001437749-22-016051","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2022-06-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nuo Therapeutics enters exclusive distribution agreement with Pacific Medical for Aurix System","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed Pacific Medical as exclusive distributor for Aurix System in six+ western states (WA, OR, ID, MT, WY, most CA, northern NV, AK).","Agreement term is 5 years, subject to standard termination and sales quota provisions.","Compensation: commission on product sales plus annual bonus if sales quotas exceeded by agreed increment.","Territory covers Pacific Northwest, most of California, and Alaska."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365071,"accession_number":"0001437749-22-010347","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2022-05-02T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Nuo Therapeutics raises $3.55M in private placement at $1.00/share with insider participation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 3,550,000 shares of common stock at $1.00 per share for gross proceeds of $3,550,000.","Insider investors include CEO/CFO David Jorden ($10,532), director Scott Pittman ($100,000), COO Peter Clausen ($25,000), and principal holder Charles Sheedy ($804,868).","Proceeds to be used for working capital; post-offering shares outstanding increase to 40,674,205.","Shares issued under Section 4(a)(2) and Rule 506 in unregistered transaction; company not current in SEC reports."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384668,"accession_number":"0001437749-22-000240","cik":1091596,"company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","form_type":"8-K","filed_at":"2022-01-04T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Nuo Therapeutics modifies warrant exercise price; all warrants exercised for 6.87M shares and $1.37M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warrant exercise price reduced from $0.40 to $0.20 per share, with exercise required by Jan 31, 2022.","All 6,865,461 warrants exercised by Dec 30, 2021, raising $1,373,092 in gross proceeds.","Company issued 6.87M shares of common stock in exempt private placement under Section 4(a)(2) and 3(a)(9).","Warrants were originally issued in October 2020 recapitalization and for services to executives including CEO David Jorden."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":47924639.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}